SCHEMBL6997271

SCHEMBL6997271

CCOC(=O)c1c(Nc2ccc(Cl)cc2N)sc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 2/20 0.42
ALOX12 P18054 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CDC25B P30305 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6996720 0.92 MAPT (0.44) MAPTSMN1; SMN2LMNAALOX12ALDH1A1
SCHEMBL6998866 0.89 CISD2 (0.45) MAPTSMN1; SMN2LMNAALOX12ALDH1A1
SCHEMBL6997161 0.88 MAPT (0.44) MAPTSMN1; SMN2LMNAALOX12ALDH1A1
SCHEMBL7000437 0.88 SMN1; SMN2 (0.43) MAPTSMN1; SMN2LMNAALOX12ALDH1A1
SCHEMBL6999000 0.88 IDO1 (0.44) MAPTSMN1; SMN2LMNAALOX12ALDH1A1
SCHEMBL7696889 0.88 MAPT (0.44) MAPTLMNAALOX12ALDH1A1KDM4E
SCHEMBL6994066 0.87 SMN1; SMN2 (0.54) MAPTSMN1; SMN2LMNAALOX12ALDH1A1
SCHEMBL6993923 0.87 MAPT (0.49) MAPTSMN1; SMN2LMNAALDH1A1KDM4E
SCHEMBL6992508 0.85 LMNA (0.47) MAPTSMN1; SMN2LMNAALOX12ALDH1A1
SCHEMBL7002745 0.84 MAPT (0.44) MAPTSMN1; SMN2LMNAALOX12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885SMN1; SMN2 1349/4885LMNA 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.